This article is more than 5 years old. Information may no longer be current.
Mobile-bearing medial UKA yielded good survivorship, outcomes at 10 years
At 10-year follow-up, patients who underwent Oxford mobile-bearing medial unicompartmental knee arthroplasty experienced good survivorship and excellent outcomes, according to results.
Adolph V. Lombardi Jr., MD, and colleagues performed a retrospective review of 695 patients who underwent 825 medial unicompartmental knee arthroplasty (UKA) procedures through the minimally invasive surgical approach. Surgeons who performed the procedures used the phase 3 mobile-bearing cemented Oxford Knee (Zimmer Biomet), which was implanted using phase 3 instrumentation.
During the study, 93 knees were revised at a mean follow-up of 9.7 years. At 10 years, researchers found a 90% implant survivorship and 85% UKA survivorship.
“Lateral compartment osteoarthritis progression was the most common cause for revision while tibial aseptic loosening was the second highest cause for revision,” Lombardi told Healio.com/Orthopedics. “Interestingly, BMI did not affect survivorship of the implant.”
Results showed an average American Knee Society Score knee score of 49 preoperatively, which increased postoperatively to 90. Researchers also noted an average American Knee Society Score for function of 55 preoperatively. This also increased postoperatively to 77.
“As part of the FDA approval process, all surgeons performing mobile-bearing unicompartmental knee arthroplasty are required to undergo specialized training,” Lombardi said. “Since its introduction in 2004, over 75 courses have been completed training over 5,800 U.S. surgeons. With the backdrop of its 40-year history, mobile-bearing unicompartmental knee arthroplasty remains an appropriate and viable option for patients who present with anteromedial osteoarthritis.” – by Casey Tingle
Disclosures: Lombardi reports he receives royalties from Zimmer Biomet and Innomed; is a paid consultant for Zimmer Biomet; owns minority interest in SPR Therapeutics, VuMedi, ElutiBone and Joint Development Corporation; receives research support from Zimmer Biomet, Pacira Pharmaceuticals and SPR Therapeutics; and is a board or committee member for Operation Walk USA, The Hip Society, The Knee Society and Mount Carmel Education Center at New Albany. Please see the full study for a list of all other authors’ relevant financial disclosures.